Incyte Biosciences International Sàrl

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
-
Website

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

First Posted Date
2022-05-04
Last Posted Date
2023-09-15
Lead Sponsor
Incyte Biosciences International Sàrl
Registration Number
NCT05359692
Locations
🇺🇸

University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 14 locations

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

First Posted Date
2022-03-18
Last Posted Date
2024-07-08
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
176
Registration Number
NCT05287113
Locations
🇬🇷

Saint Lukas Clinic, Thessaloniki, Greece

🇵🇱

Przychodnia Lekarska Komed Roman Karaszewski, Konin, Poland

🇵🇱

Nzoz Provita Prolife Centrum Medyczne, Tomaszow Mazowiecki, Poland

and more 86 locations

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

First Posted Date
2019-05-01
Last Posted Date
2024-12-10
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
60
Registration Number
NCT03934372
Locations
🇮🇹

Aou Policlinico S. Orsola-Malpighi Bologna, Bologna, Italy

🇮🇹

Asst Degli Spedali Civili Di Brescia, Brescia, Italy

🇮🇹

A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita, Torino, Italy

and more 29 locations

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

First Posted Date
2018-05-25
Last Posted Date
2020-10-30
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
22
Registration Number
NCT03538028
Locations
🇺🇸

Hackensack Medical Center, Hackensack, New Jersey, United States

🇺🇸

The Angeles Clinic and Research Center, Los Angeles, California, United States

🇺🇸

Carolina BioOncology Institute, Huntersville, North Carolina, United States

and more 1 locations

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

First Posted Date
2018-05-04
Last Posted Date
2018-12-14
Lead Sponsor
Incyte Biosciences International Sàrl
Registration Number
NCT03515785
Locations
🇫🇷

University Hospital Bordeaux, Bordeaux, France

🇫🇷

University Hospital Lyon, Lyon, France

🇫🇷

University Hospital Amiens, Amiens, France

and more 7 locations

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

First Posted Date
2017-09-11
Last Posted Date
2021-07-22
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
10
Registration Number
NCT03277352
Locations
🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

First Posted Date
2017-08-07
Last Posted Date
2022-09-27
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
52
Registration Number
NCT03241173
Locations
🇺🇸

The University of Alabama Birmingham (UAB), Birmingham, Alabama, United States

🇺🇸

Mount Sinai Medical Center of Florida, Inc., Miami, Florida, United States

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 12 locations

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

First Posted Date
2017-04-24
Last Posted Date
2022-12-28
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
145
Registration Number
NCT03126110
Locations
🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

🇺🇸

Washington University - Siteman Cancer Center, Saint Louis, Missouri, United States

and more 35 locations

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-10-04
Last Posted Date
2020-05-12
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
87
Registration Number
NCT02923349
Locations
🇺🇸

Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

🇨🇭

University Hospital of Laussane (CHUV), Lausanne, Switzerland

and more 5 locations

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2016-03-03
Last Posted Date
2021-02-26
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
100
Registration Number
NCT02697591
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

MSK Westchester, Harrison, New York, United States

and more 5 locations
© Copyright 2024. All Rights Reserved by MedPath